Text Size

START Follow-up Study

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yih-Ing Hser, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT01592461
First received: May 3, 2012
Last updated: May 4, 2012
Last verified: May 2012
History of Changes
  Purpose

The purpose of the study is to conduct a follow-up of substance abuse patients (n=1,269) about 2 to 5 years since they were originally recruited from 8 substance abuse treatment clinics (located in 5 states) to participate in a prior clinical trial study called "START" (Starting Treatment with Agonist Replacement Therapies). The START Follow-up Study will be conducted over 5 years and will involve three follow-up interviews with START participants.

The specific aims of the START Follow-up Study are as follows.

  1. To determine longer-term outcomes of Suboxone versus methadone treatment received in the START
  2. To investigate patient and treatment factors associated with post-START treatment access, utilization, and outcomes among Suboxone and methadone patients
  3. To explore other correlates of the long-term outcomes among START patients.

Condition
Opioid Dependence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: START Follow-up Study (NIDA CTN Protocol 0050)

Further study details as provided by University of California, Los Angeles:

Estimated Enrollment: 1269
Study Start Date: September 2010
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Participants will include the 1,269 study participants from the original START Study (CTN-0027) that was conducted from 2006 to 2010 at eight community treatment programs (CTPs).

Criteria

Inclusion Criteria:

  • To be eligible to participate in the study, individuals must have participated in CTN-0027 START.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01592461

Locations
United States, California
Matrix Institute on Addictions
Los Angeles, California, United States, 90016
Bi-Valley Medical Clinic, Inc.
Sacramento, California, United States, 95838
BAART Programs
San Francisco, California, United States, 94102
United States, Connecticut
Hartford Dispensary
Hartford, Connecticut, United States, 06120
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
United States, Oregon
CODA, Inc.
Portland, Oregon, United States, 97214
United States, Pennsylvania
NET Steps
Philadelphia, Pennsylvania, United States, 19137
United States, Washington
Evergreen Treatment Services
Seattle, Washington, United States, 98134
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Yih-Ing Hser, Ph.D. University of California, Los Angeles
  More Information

No publications provided

Responsible Party: Yih-Ing Hser, Professor, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01592461     History of Changes
Other Study ID Numbers: CTN-0050, U10DA013045
Study First Received: May 3, 2012
Last Updated: May 4, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Los Angeles:
Substance abuse treatment outcomes
Opioid dependence
Suboxone
Methadone

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 19, 2013